Frank Hermann
University of Zurich
16 Papers
136 Citations
Frank Hermann is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Rheumatoid arthritis. The author has an hindex of 8, co-authored 16 publications.
Chat about Author
Papers
Simvastatin improves endothelial function in patients with rheumatoid arthritis.
Frank Hermann,Adrian Forster,Rémy Chenevard,Frank Enseleit,David Hürlimann,Roberto Corti,Lukas E. Spieker,Diana Frey,Matthias Hermann,Walter F. Riesen,Michel Neidhart,Beat A. Michel,Jens P. Hellermann,Thomas F. Lüscher,Georg Noll,Frank Ruschitzka +15 more
TL;DR: To the Editor: Rheumatoid arthritis (RA) is the most common systemic connective tissue disease and affects 2.1 million people in the U.S., 1.5 million of whom are women, which shortens life expectancy by about one year.
118
Protection of endothelial function: targets for nutritional and pharmacological interventions.
Isabella Sudano,Lukas E. Spieker,Frank Hermann,Andreas J. Flammer,Roberto Corti,Georg Noll,Thomas F. Lüscher +6 more
TL;DR: Novel therapeutic strategies specifically targeting inflammation thus bear great potential for the prevention and treatment of atherosclerotic vascular disease, particularly with regard to enhanced NO synthesis and endothelial function observed in humans following consumption.
74
Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial
Andreas J. Flammer,Nhung T. T. Vo,Bruno Ledergerber,Frank Hermann,Andrea Gämperli,Angela Huttner,John Evison,Iris Baumgartner,Matthias Cavassini,Daniel Hayoz,Kurt Quitzau,Martin Hersberger,Isabella Sudano,Frank Ruschitzka,Thomas F. Lüscher,Georg Noll,Rainer Weber +16 more
TL;DR: The switch from another PI to atazanavir in treatment-experienced patients did not result in improvement of endothelial function despite significantly improved serum lipids.
Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia
Frank Hermann,Frank Enseleit,Lukas E. Spieker,Daniel Périat,Isabella Sudano,Matthias Hermann,Roberto Corti,Georg Noll,Frank Ruschitzka,Thomas F. Lüscher +9 more
TL;DR: In patients with type II hyperlipidemia, CETP inhibition with JTT-705 increased HDL-C and lowered triglycerides but improved endothelial function in the subgroup of patients with low baseline HDL- C levels only.
42